Esophagus Cancer, Adenocarcinoma
Conditions
Keywords
urokinase plasminogen activator receptor, uPAR, Cardia, Adenocarcinoma, Immunohistochemistry
Brief summary
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.
Detailed description
* Sections of the tumor tissue will be HE stained. * Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry. * Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern. * A semiqualitative scale corresponding to the level of uPAR expression will be made. * Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern. * An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.
Interventions
OTHERuPAR immunohistochemistry
Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
Sponsors
Michael Patrick Achiam
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
The patients will be drawn from the existing clinical biobank. The biobank is located at the department of pathology, Rigshospitalet. From this clinical biobank, a new temporary research biobank will be made. Supplementary sections from formalin-fixed paraffin embedded (FFPE) blocks containing tumor tissue will be cut and Haematoxylin and eosin (HE) and immunohistochemical (IHC) staining will be performed.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years old. * Patients who underwent curatively intended surgery for gastroesophageal cancer * Patients who underwent surgery after 01-01-2016.
Exclusion criteria
* Patients who applied for an exception from medical research at the National Registry of Tissue Use. * Patients with other histological subtypes than adenocarcinoma.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| uPAR microexpression | Up to 6 months | Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively. This will be done by a pathology analysis of gastroesophageal cancer resections. |
| Tumor-to-background ratio | Up to 6 months | A pathology staining will determine the uPAR in the tumor compared with the healthy cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| uPAR in patient groups | Up to 6 months | Baseline statistical analysis of patient groups and their expression of uPAR in their resected tumor tissues will be made. |
Countries
Denmark
Outcome results
None listed